Clinical Commissioning Policy Proposition:
Obesity surgery for children with severe complex obesity

Reference: NHS England A05X03/01
Information Reader Box (IRB) to be inserted on inside front cover for documents of 6 pages and over, with Publications Gateway reference number assigned after it has been cleared by the Publications Gateway Team. Publications Gateway guidance and the IRB can be found on the Intranet.
Clinical Commissioning Policy Proposition: 
Obesity surgery for children with severe complex obesity

Reference: NHS England A05X03/01

First published: February 2016

Prepared by NHS England Specialised Commissioning Team

Published by NHS England, in electronic format only.

Classification: OFFICIAL

The National Health Service Commissioning Board was established on 1 October 2012 as an executive non-departmental public body. Since 1 April 2013, the National Health Service Commissioning Board has used the name NHS England for operational purposes.
Contents

Equality Statement .................................................................................................................. 4
Plain Language Summary ....................................................................................................... 4
1. Introduction .......................................................................................................................... 5
2. Proposed Intervention and Clinical Indication .................................................................. 5
3. Definitions ........................................................................................................................... 6
4. Aim and Objectives ............................................................................................................. 7
5. Epidemiology and Needs Assessment ................................................................................ 7
6. Evidence Base ..................................................................................................................... 7
7. Proposed Criteria for Commissioning ................................................................................ 11
8. Proposed Patient Pathway .................................................................................................. 11
9. Proposed Governance Arrangements ............................................................................... 12
10. Proposed Mechanism for Funding .................................................................................... 13
11. Proposed Audit Requirements ........................................................................................... 13
12. Documents That Have Informed This Policy Proposition ................................................ 13
13. Date of Review .................................................................................................................... 13
Equality Statement
NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation.

Plain Language Summary
The policy proposition aims to confirm NHS England's commissioning approach to obesity surgery for children (up to 18 years) with severe and complex obesity.

Childhood and adolescent obesity is a major and growing health problem. Obesity can lead to a number of serious conditions, such as hypertension, insulin resistance and metabolic syndrome, and is associated with a lower life expectancy.

For most people, eating a healthy, reduced-calorie diet and exercising regularly is the most effective treatment for obesity. Some patients may benefit from psychological support from a trained healthcare professional, to help change the way they think about food and eating. Specialist weight management programmes are also available, although are often designed for adults. If lifestyle changes alone are not successful, pharmacological treatments may be considered. If patients do not respond to the above non-invasive therapies, obesity surgery, which refers to any surgical treatment for obesity (e.g. gastric bypass), may be considered.

NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of obesity surgery for children (up to 18 years) with severe and complex obesity for a small number of highly selected patients.
1. Introduction

This document describes the evidence that has been considered by NHS England in formulating a proposal to routinely commission obesity surgery for children with severe and complex obesity for a small number of highly selected patients.

This document also describes the proposed criteria for commissioning, proposed governance arrangements and proposed funding mechanisms.

For the purpose of consultation NHS England invites views on the evidence and other information that has been taken into account as described in this policy proposition.

A final decision as to whether obesity surgery for children with severe and complex obesity for a small number of highly selected patients will be routinely commissioned is planned to be made by NHS England by June 2016 following a recommendation from the Clinical Priorities Advisory Group.

2. Proposed Intervention and Clinical Indication

The prevalence of childhood obesity has been increasing over the last few decades, and in 2011, 3 in 10 children aged 2-15 years were found to be overweight or obese in the UK (NICE CG189, 2014). Childhood obesity is associated with co-morbid conditions, commonly hypertension, obstructive sleep apnoea, insulin resistance, metabolic syndrome, non-alcoholic fatty liver disease and dyslipidaemia. The cost of obesity to society was estimated in 2007 to be £16 billion, and if rates continue to rise could reach up to £50 billion in 2050 (NICE CG189, 2014).

Obesity in children is currently managed predominately with lifestyle interventions, focusing on behavioural and dietary modifications, with evidence of short term success (Cochrane Review, 2009). Pharmacotherapy is less commonly used in adolescent patients: Cochrane review (2009) showed both Orlistat and Sibutramine in children greater than 12 years to be beneficial in reducing weight at 6 months. Some severely obese adolescents with significant and severe obesity-related comorbidities such as hypertension, fatty liver disease or uncontrolled diabetes, who have failed specialist multi-component, intensive, non-invasive weight management programmes, may be benefit from a surgical approach.

Currently there is no evidence based care pathway in utilising obesity surgery in the paediatric/adolescent population. Primarily three types of obesity surgery are being commonly performed in the paediatric/adolescent population: laparoscopic Roux-en Y gastric banding (RYGB); laparoscopic adjustable gastric banding (LAGB); and more recently sleeve gastrectomy (LSG).
3. Definitions

Obesity: term used to describe somebody who is very overweight, with a lot of body fat.

Body mass index (BMI): measure (kg/m²) of whether an adult is healthy weight for height.

BMI SD: standard deviation score indicates how many units (of the standard deviation) a child’s BMI is above or below the average BMI value for their age group and sex. Also referred to as a z score.

Co-morbidity: the presence of one or more additional diseases co-occurring with a primary disease (synergistic or coincidental); or the effect of such addition disease (clinically dominant).

Dyslipidaemia or high cholesterol: means that there is an imbalance of fats (lipids), circulating in your blood stream. Cholesterol is a fatty substance your body uses to make hormones and metabolize food.

Obesity surgery: also known as bariatric surgery, any surgical treatment for obesity.

Laparoscopic adjustable gastric band (LAGB, or gastric banding): helps reduce the amount of food eaten. It acts like a belt around the top portion of the stomach, creating a small pouch. Patients feel full after eating only a small quantity of food. It is adjustable and reversible.

Roux–en–Y gastric bypass (RNY): the most popular variation of gastric bypass operation conducted in the UK. At surgery, the top section of the stomach is divided off by a line of staples, creating a small ‘pouch’ stomach. A new exit from this pouch is made into a ‘Y’ loop from the small intestine so that food bypasses the old stomach and part (about 100-150cm) of the small intestine. The size of stomach pouch and the length of small intestine that is bypassed are carefully calculated to ensure that patients will be able to eat enough for their body’s needs at normal weight.

Sleeve gastrectomy: the sleeve gastrectomy reduces the size of the stomach by about 75%. It is divided vertically from top to bottom leaving a banana shaped stomach along the inside curve, and the pyloric valve at the bottom of the stomach, which regulates the emptying of the stomach into the small intestine, remains intact. This means that although smaller, the stomach function remains unaltered.

Gastric balloon: an intra-gastric balloon is a soft silicone balloon that is surgically implanted into the stomach. The balloon is filled with air or saline solution (sterile salt water), and so takes up some of the space in the stomach. This procedure is only temporary, and the balloon is usually removed after six months.

Models of care: a typical model for managing obesity is outlined as follows:
- Tier 4 - Specialised Complex Obesity Services (including both medical management, obesity surgery and other elements of specialised MDT care)
- Tier 3 - A specialist multi-disciplinary team (MDT) to provide an intensive level of input to patients
4. Aim and Objectives

This policy proposition aims to define NHS England's commissioning position on obesity surgery as part of the treatment pathway for children (up to 18 years) with severe and complex obesity.

The objective is to ensure evidence based commissioning with the aim of improving outcomes for children with severe and complex obesity.

5. Epidemiology and Needs Assessment

Childhood and adolescent obesity is a major and growing health problem and associated with comorbid conditions, commonly hypertension, obstructive sleep apnoea, insulin resistance, metabolic syndrome, non-alcoholic fatty liver disease and dyslipidaemia.

The prevalence of childhood obesity has been increasing over the last few decades, and in 2011, 3 in 10 children aged 2-15 years were found to be overweight or obese in the UK (NICE CG189). Rates of obesity surgery are also increasing: there was 1 operation in 2000 and 31 in 2009 (Jones Nielson et al, 2013). Around 6-8 patients receive obesity surgery each year, based on an average across the 30-40 undertaken over the last 5 years (data from policy working group) and data from the National Bariatric Surgery Registry (2014) that shows that 23 primary operations for patients aged 12 – 17 were undertaken between 2011 – 2013.

6. Evidence Base

NHS England has concluded that there is sufficient evidence to support a proposal for the routine commissioning of obesity surgery for children with severe and complex obesity for a small number of highly selected patients.

What is the clinical effectiveness of obesity surgery in children and adolescents?
Is there any evidence for long term efficacy (more than 1 year? more than 5 years?)?

Overall, in the current literature there is evidence of clinical effectiveness for obesity surgery in adolescents (following skeletal maturity - Tanner Stage 4 and above), predominately from non-RCT studies (level 2 and 3 studies), with limited evidence about long term efficacy. There are limited studies on performing obesity surgery in younger children (level 3). There is insufficient evidence on selection criteria, indications, postoperative complications and long-term adverse effects of surgery. Although included in
the literature search strategy, no evidence relating to duodenal switch procedures in adolescents could be found. The search strategy did not specifically include rare syndromes predisposing to adolescent obesity, but some pertinent information was found in the wider literature.

One RCT (level 1) by O’Brien et al, 2010 has been identified in the current literature, which evaluated laparoscopic adjustable gastric banding (LAGB) with intensive lifestyle intervention (dietary and behavioural modification) in 50 obese adolescents aged 14-18. They found that LAGB resulted in substantial weight loss at two years, with a mean reduction of 34.6kg versus 3kg in the lifestyle group. They also observed improvements in health related quality of life. Twenty-eight percent of adolescents did require revision surgery (removal or replacement of the band or replacement of the access port), a rate consistent with adult studies.

A recent meta-analysis (level -1) by Paulus et al (2015) examined change in BMI one year post operatively, and reported on health related indices. The analysis included 23 studies (level2/3), and found the mean BMI loss was -13.5kg/m², the greatest loss in the RYGB group (-17.2kg/m²) and smallest in the LAGB group (-10.5kg/m²). These findings were consistent with another meta-analysis that evaluated 37 studies (Black et al, 2013) (level -1), and found the mean BMI loss was greatest in the RYGB group (-16.6kg/m²), followed by LSG with 14.1kg/m² and LAGB with -11kg/m². Pedroso et al (2015) (level -2) assessed LSG and LAGB in adolescent patients and at two year follow-up observed significant greater percentage excess weight loss in the LSG group compared to the LAGB group (70.9% vs 35.5% respectively P=0.004). The recently published Teen longitudinal Assessment of Bariatric surgery (Teen-LABS) study (Inge et al, 2015) showed that patients who underwent obesity surgery (RYGB and LSG) reported an overall decrease in mean weight of 27% and mean BMI decrease of 28% (BMI decreased from baseline from 53kg/m² to 38kg/m²) at 3 years post operatively. The mean weight loss of those patients who underwent RYGB was 28% compared to 26% in the LSG group at three years. The study observed that at three years 26% of patients were no longer obese. At 3 years 2% of patients who underwent gastric bypass and 4% of those who underwent sleeve gastrectomy exceeded baseline weight.

Paulus et al (2015) noted the overall poor quality of documentation of complications, with the majority of complications in the RYGB group involving nutrient deficiencies, hernia and wound infection. In LAGB the key complications were pouch dilatation, band slippage and port complications. Complications were rarely reported in LSG. Pedroso et al (2015) observed that at 5 years the complication rate in the LAGB group was 23.4%, which included bowel obstruction, port leakage and band displacement. Follow-up at two years in the LSG group reported minimal overall complications. However, there was one death 12 days post LSG, as a result of mesenteric venous thrombosis. The Teen Longitudinal Assessment of Bariatric surgery (Teen-LABS) (n=242) (level 3), which is an ongoing prospective study, evaluated outcomes within 30 days postoperatively (Inge et al, 2014). No mortality was recorded, 7.9% experienced major complications, 5% perioperative complications including one splenic injury, early reoperation for intestinal obstruction, bleeding or suspected gastrointestinal leak. 14.9% had minor complications including urinary tract infections, abdominal and gastrointestinal complaints including dehydration. The Teen-LAB study at 3 years post operatively (Inge et al 2015) found 13% of patients had undergone one or more intra-abdominal procedure. Inge et al also evaluated
micronutrients, and found low ferritin levels were evident in 57% of patients (P<0.001), 16% of patients who underwent RYGB (P=0.008) and 8% of all patient being VitB12 deficient, at three years post-surgery. Case series of 345 patients Lennez et al (2014) reported intraoperative complications rate of 0%-2.6%, and postoperative complications (18 months follow-up) rate of 9.1% to 2.5%. In this case series they found no difference in rates of complications at 18 months amongst the three surgical procedures (LSG, LAGB and RYGB). Long-term high quality studies are required to evaluate the risk of different obesity surgical procedures in children and adolescents.

In studies reporting co-morbidities a variability in both the assessment and methodology is evident. There is level 2/3 evidence of improvement and resolution of co-morbidities. Paulus et al (2015) found that over 50% of the RYGB and LGB reported resolution in associated co-morbidities, including hypertension, sleep apnoea, insulin resistance and dyslipidaemia. Black et al (2013) reported, 11/18 LAGB studies observed complete resolution of hypertension in 22-100% of studies, dyslipidaemia in 50% and 100% of diabetic cases after surgery. In RYGB 8/13 reported an improvement, and in LSG 4/5 studies reported resolution of co-morbidities in 75-100% of studies evaluating hypertension, 56-100% of dyslipidaemia and 50-93% of those with diabetes. Inge et al (2015) observed (level 3) an improvement in insulin sensitivity and β cell function, and metabolic improvements even with obesity persisting at one year follow-up.

Psychosocial and mental health is increasingly becoming an important parameter requiring evaluation pre and post obesity surgery. A systematic review consisting of 12 adolescent studies (Herget et al, 2014) (level 2+) reported depressive symptoms ranging from 15 to 70%, anxiety symptoms 15-33% and eating disorders in 48-70%, prior to surgery. A large case series by Sysko et al (2012) reported a significant improvement in depressive symptoms (P<0.001) at 15 months. A systematic review evaluating 10 studies (Hilstrom et al, 2015 (level 2+)) observed an overall improvement in psychosocial outcomes post operatively. Herget et al (2014) found studies varied in evaluation in time points and no clear documentation of pharmacotherapy pre and post-surgery. Studies have observed short term improvements in psychosocial parameters, however studies have also reported a persistence of symptoms post operatively. Zeller et al (2011) observed an increased tendency of depressive symptoms at 18-24 months postoperatively, and Orsorio et al (2011) observed 21.4% of patients were still suffering from clinical depressive symptoms. Overall studies (level2/3) have reported improvement in quality of life parameters, physical, self-esteem domains from baseline following obesity surgery, further high level evidence is required to further evaluate the psychosocial impact upon adolescents/children pre and post-surgery.

Cost effectiveness

There is lack of studies evaluating cost effectiveness of obesity surgery in children and adolescents. Aikenhead at al (2011) in a systematic review identified three studies on LAGB in adolescent, that showed net cost saving per disability adjusted life year was $AU4,400 (£2,092) (level 2+). Bairdain et al (2015) (level 3) evaluated cost-effectiveness (n=11) and estimated that obesity surgery was not cost effective in the first three years, but cost effective after that $80,065 (£52,925) QALY in year four and $36,570 (23,515) QALY...
in year seven (threshold of $100,000/QALY). This small study failed to include obesity specific comorbidities, and additionally the US findings may not be entirely applicable to the UK population cohort.

What is the evidence for selection criteria and previous weight management strategies?

There is no empirical evidence of a standardised care pathway, including selection criteria. The majority of the western world follows consensus guidance, including that obesity surgery should be performed on adolescents following a multidisciplinary evaluation. Obese adolescents (≥40kg/m² or ≥35kg/m² with at least one obesity associated co-morbidity) that have achieved skeletal maturation (linear growth), following failure of lifestyle interventions should be considered. There is a variation and documentation in the studies in type, intensity and duration of lifestyle intervention prior to obesity surgery. The majority of obesity surgery appeared to be performed in a multidisciplinary environment. The majority of studies have excluded syndromic patients, those with severe medical or psychiatric problems and those who have disease related aetiology for obesity.

Patient participation prior to surgery provides an opportunity to evaluate behaviour and motivation. Fenning et al (2015) pilot study (n=15) (level 3) involved two phases, firstly a 3 month preoperative program, consisting of medical examination, psychological measures, self-monitoring, physical activity, cognitive behaviour orientated therapy and psychosocial educational training, and phase two surgical phase. Phase I assessed adherence to program, parental involvement and weight loss preoperatively. They found both weight and BMI decreased over the three months, mean loss -3.1kg/m² and majority of patients followed the program. Interestingly, they observed poor parental participation. Compliance post operatively requires further evaluation.

Although the majority of surgery has been undertaken in non-syndromic adolescent, a recent study by Mohaidly et al (2013) (Level 3) performed LSG on an obese 2.5 year old, and at 2 years the patient had a 27% weight loss with normalisation of BMI from 41kg/m² to 24kg/m². The authors did raise concern on parental compliance with instructions and poor attendance at follow-up. Growth, developmental and nutritional details were not included in the study. Alqahtani et al (2015) (level -2) performed LSG on 24 patients with Prader Willi Syndrome (PWS) with a mean age of 10.7 years, observed at 5 years significant weight reduction, with rate of growth not significant between the PWS group and matched non-PWS group.

In summary, the available evidence indicates that any of these three procedures in adolescents lead to greater short–term (1-3 years) weight loss and improvements in HRQOL, psychological outcomes and comorbidities than non-invasive management alone, although there is little longer term follow-up evidence available at present. There was little evidence to indicate that one type of procedure was superior or inferior to another, and the adverse effects of obesity surgery in general are not well documented. The collection of longitudinal evidence on the short and long-term effects of obesity surgery in children, including endocrinological and metabolic effects, raises the importance of robust mechanisms to assess longer term outcomes and to ensure patients are in a position to give informed consent for the procedure.
7. Proposed Criteria for Commissioning

Surgical intervention is not generally recommended in children or young people (NICE CG189, 2014). However, obesity surgery may be considered in eligible individuals to achieve significant and sustainable weight reduction, if all the following criteria are fulfilled:

- The adolescent has been evaluated by the appropriate specialised MDT (see service specification for details) and deemed suitable appropriate for surgery.

- The adolescent has a post pubertal BMI ≥40kg/m² (BMI SD ≥3.0) or ≥35kg/m² (BMI SD ≥3.5) with significant associated comorbidities that are both predicted to have the potential to progress and are amenable to improvement/ resolution by weight loss. Obesity should have been present for several years.

- The adolescent has achieved physiological maturity (Tanner Stage 4 or above).

- The adolescent has completed clinical assessment and management treatment within a commissioned Tier 3 service.

- The decision of the MDT regarding surgery will depend on the individual's engagement and response to weight management services, their co-morbidities and risk–benefit analysis. This analysis should assess the short and long term risks of not operating versus the risks associated with surgery. In addition psychological factors, motivation/compliance, learning difficulty issues and impact on education will also be taken into account.

- The adolescent is generally fit for anaesthesia and surgery.

- The adolescent and their family commits to the need for long-term follow-up.

- Adolescents with syndromic or monogenic obesity will also be discussed by the MDT on a case by case basis and arrangements made by the MDT to seek further national expert advice/opinion on the ethical issues and supporting research.

8. Proposed Patient Pathway

Before being considered for surgery, the adolescent must have completed assessment and treatment within a commissioned Tier 3 service. It is expected that the Tier 3 service will have identified, investigated and managed the associated comorbidities prior to referral for surgical assessment to a Tier 4 service. The adequacy, intensity and duration of intervention/s will be determined by the specialist MDT: adolescents should remain in Tier 3 until all non-surgical avenues have been adequately explored and found to be unsuccessful; these approaches should be documented in the MDT discussions.
Adolescents indicated for obesity surgery should have a comprehensive clinical, psychological, educational, family and social assessment by an appropriate specialised multi-disciplinary team before undergoing surgery. This includes a full medical evaluation, and genetic screening or assessment to exclude rare, treatable causes of obesity.

Surgical care and follow-up should be coordinated around the patient and his/her family's needs, complying with the approaches outlined in the Department of Heath's "A call to action on obesity in England" to increase attendance and compliance. Lifelong specialist follow up is advocated, with a minimum 5 year follow up care plan recommended, including transfer into the adult pathway at 18 years old where appropriate (in line with the the principles outlined in the NICE guidance 'Transition from children's to adults' services' in development), or follow up beyond 18 years old in tertiary paediatric services or Tier 4 paediatric obesity services where adolescents are within a few years of surgery or where local adult provision is weak.

Adolescents who have had obesity surgery should have a follow-up care plan for a minimum of 5 years within the Tier 4 obesity service, or through shared care follow up arrangements with the latter and more local specialist paediatric centres. This should include:
- monitoring nutritional intake (including protein and vitamins) and mineral deficiencies
- monitoring for comorbidities
- medication review
- dietary and nutritional assessment, advice and support
- physical activity advice and support
- psychological support tailored to the individual
- information about professionally-led or peer-support groups.

See the NHS service specifications for more details.

9. Proposed Governance Arrangements
Providers, surgeons, premises, on site services and obesity surgery throughput should at least meet the IFSO Guidelines for Safety, Quality, and Excellence in Bariatric Surgery.

There must be appropriate specialised MDT composition, specialist professional inputs and process design for all stages of the pathway (elective and emergency). In addition, organisational arrangements for patient safety (elective and emergency) should be risk assessed, regularly tested and improved. Protocols should be audited especially the use of questionnaires for clinical assessment, generic interdisciplinary roles and substitution / expansion of professional roles, i.e. use of GPs or other therapists for band-fills as an alternative to consultant radiologists; use of Skype, telephone etc. for consultations.

The surgical service should be seamless both pre- and post-operatively with the medical specialist Tier 3 / 4 service and determined by local arrangements.

The obesity surgical and medical provider will be responsible for the organisation of structured, systematic and team based follow up for a minimum of 5 years. The latter provider will make arrangements to hand over care to the adult Tier 3 service when the
adolescent reaches 18 years if appropriate, with the option of continued follow up beyond 18 in paediatric services or Tier 4 paediatric led services, where adolescents are within a few years of surgery or where local adult provision is weak.

Follow up rates and nutritional/metabolic complications should be published.

### 10. Proposed Mechanism for Funding

Specialised complex obesity services, including obesity surgery pre-assessment, perioperative management, postoperative and longer term follow up where it occurs within the specialised service will be funded by NHS England.

### 11. Proposed Audit Requirements

Mandatory compliance by obesity surgery providers with National Bariatric Surgery Registry (NBSR) requirements, including 100% provision of required data, and publication of long term follow up data.

Given the relative lack of evidence relating to adverse effects (e.g. nutritional deficiencies) in the adolescent population, it would be beneficial for specific outcome requirements to be included in the NBSR dataset and published, to support longitudinal study. See specification for suggested outcome measures.

### 12. Documents That Have Informed This Policy Proposition

- Clinical commissioning policy: complex and specialised obesity surgery NHSCB/A05/P/a
- Obesity: identification, assessment and management of overweight and obesity in children, young people and adults NICE clinical guidelines 189
- NICE guidance in development Transition from children's to adults' services GID-SCWAVE0714, expected publication date February 2016

### 13. Date of Review

This document will lapse upon publication by NHS England of a clinical commissioning policy for the proposed intervention that confirms whether it is routinely or non-routinely commissioned (expected by June 2016).